Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study.

Rizvi AA, Patti AM, Giglio RV, Nikolic D, Amato A, Al-Busaidi N, Al-Rasadi K, Soresi M, Banach M, Montalto G, Rizzo M

Expert opinion on biological therapy20 Jul 2015Cited by 38 (Europe PMC)

PMID26195184DOI10.1517/14712598.2015.1067299PepBankPUB-26195184

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes with or without NAFLD, glycated hemoglobin fell significantly in both groups during liraglutide treatment.
In plain wordsIn adults with type 2 diabetes, with or without fatty liver, liraglutide treatment lowered HbA1c in both groups.
Peptide
Liraglutide
Outcome
DecreaseGlycated hemoglobin
Study
n = 58
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg/day for 2 weeks, then 1.2 mg/day · 8 monthsAs given in this study (human).
Source sentences
Summary
Glycated hemoglobin reduced significantly in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years).
Summary · context
Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.
Report a problemFND-2619518401
02HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes with or without NAFLD, body weight did not change significantly during liraglutide treatment.
In plain wordsIn adults with type 2 diabetes, body weight did not change significantly with liraglutide.
Peptide
Liraglutide
Outcome
No significant changeBody weight
Study
n = 58
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6 mg/day for 2 weeks, then 1.2 mg/day · 8 monthsAs given in this study (human).
Source sentences
Summary
No significant changes were found in body weight, waist circumference and lipids.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years).
Summary · context
Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.
Report a problemFND-2619518402
03HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes with or without NAFLD, waist circumference did not change significantly during liraglutide treatment.
In plain wordsIn adults with type 2 diabetes, waist size did not change significantly with liraglutide.
Peptide
Liraglutide
Outcome
No significant changeWaist circumference
Study
n = 58
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6 mg/day for 2 weeks, then 1.2 mg/day · 8 monthsAs given in this study (human).
Source sentences
Summary
No significant changes were found in body weight, waist circumference and lipids.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years).
Summary · context
Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.
Report a problemFND-2619518403
04HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes with or without NAFLD, lipids did not change significantly during liraglutide treatment.
In plain wordsIn adults with type 2 diabetes, blood fat levels did not change significantly with liraglutide.
Peptide
Liraglutide
Outcome
No significant changeLipids
Study
n = 58
Outcome group
Lipids · Metabolic and weight
Studied dose
0.6 mg/day for 2 weeks, then 1.2 mg/day · 8 monthsAs given in this study (human).
Source sentences
Summary
No significant changes were found in body weight, waist circumference and lipids.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years).
Summary · context
Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.
Report a problemFND-2619518404
05HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes and NAFLD, carotid intima-media thickness decreased significantly during liraglutide treatment (p = 0.0325).
In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide treatment was followed by a thinner carotid artery wall.
Peptide
Liraglutide
Outcome
DecreaseCarotid intima-media thickness in T2DM with NAFLD
Study
n = 29
Outcome group
Heart function · Cardiovascular
Studied dose
0.6 mg/day for 2 weeks, then 1.2 mg/day · 8 monthsAs given in this study (human).
Measurements
carotid IMT at baseline
0.96 mm
T2DM with NAFLD
carotid IMT at 8 months
0.85 mm
T2DM with NAFLD
Source sentences
Summary
Carotid IMT decreased significantly in the T2DM patients with NAFLD (from 0.96 ± 0.27 to 0.82 ± 0.17 to 0.85 ± 0.12 mm, p = 0.0325), but not in the T2DM patients without NAFLD (from 0.91 ± 0.23 to 0.88 ± 0.17 to 0.85 ± 0.15 mm, p = 0.4473).
2 context sentences(design, population, supporting numbers)
Summary · context
In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years).
Summary · context
Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.
Report a problemFND-2619518405
06HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes without NAFLD, carotid intima-media thickness did not change significantly during liraglutide treatment (p = 0.4473).
In plain wordsIn adults with type 2 diabetes without fatty liver, the carotid artery wall thickness did not change significantly with liraglutide.
Peptide
Liraglutide
Outcome
No significant changeCarotid intima-media thickness in T2DM without NAFLD
Study
n = 29
Outcome group
Heart function · Cardiovascular
Studied dose
0.6 mg/day for 2 weeks, then 1.2 mg/day · 8 monthsAs given in this study (human).
Measurements
carotid IMT at baseline
0.91 mm
T2DM without NAFLD
carotid IMT at 8 months
0.85 mm
T2DM without NAFLD
Source sentences
Summary
Carotid IMT decreased significantly in the T2DM patients with NAFLD (from 0.96 ± 0.27 to 0.82 ± 0.17 to 0.85 ± 0.12 mm, p = 0.0325), but not in the T2DM patients without NAFLD (from 0.91 ± 0.23 to 0.88 ± 0.17 to 0.85 ± 0.15 mm, p = 0.4473).
2 context sentences(design, population, supporting numbers)
Summary · context
In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years).
Summary · context
Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.
Report a problemFND-2619518406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT01715428

Liraglutide and Cardio-Metabolic Risk Markers

University of Palermon = 300Jun 2012 to Dec 2015

Type-2 Diabetes

Trial page ClinicalTrials.govUpdated 22 Nov 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.